“
TL;DR
It highlights the phase II CRATUS trial, which found that intravenous Lomecel-B (a mesenchymal stem cell preparation) significantly improved the 6-minute walk distance in frail older adults.
Frontiers in Aging · 1 author, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It highlights the phase II CRATUS trial, which found that intravenous Lomecel-B (a mesenchymal stem cell preparation) significantly improved the 6-minute walk distance in frail older adults.
The trial reported that Lomecel-B was well tolerated and significantly increased the 6-minute walk distance (6MWD), with a maximum increase of 64 meters at the 100-million-cell dose. A significant reduction in serum TNF-alpha levels was also observed. The review notes that current trials have limitations, including a lack of standard protocols, limited pharmacokinetic data, and challenges studying poly-medicated older adults with comorbidities. It also covers other trials for frailty and facial skin aging, such as an RCT showing SVF-assisted autologous fat grafting improves skin quality.